MAM01 / Atreca, Bill & Melinda Gates Foundation 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
MAM01 / Atreca, Bill & Melinda Gates Foundation
NCT06408857: Study To Evaluate Safety, Tolerability, and Pharmacokinetics of MAM01 in African Population

Not yet recruiting
1
139
RoW
MAM01 300 mg SC, MAM01 300 mg IM, MAM01 2000 mg IV, MAM01 190 mg SC, MAM01 225 mg SC, MAM01 150 mg SC, MAM01 100 mg SC, MAM01 150 mg IM, MAM01 150 mg IV, Placebo SC, Placebo IV, Placebo IM
Bill & Melinda Gates Medical Research Institute
Healthy Volunteers
01/26
01/26
NCT05891236: Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults

Recruiting
1
61
US
MAM01 1.5 mg/kg, Placebo, MAM01 5 mg/kg, MAM01 10 mg/kg, MAM01 40 mg/kg, MAM01 450 mg, Control, MAM01 600 mg, MAM01 900 mg
Bill & Melinda Gates Medical Research Institute
Malaria
12/24
06/25

Download Options